Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > latest news release
View:
Post by DJDawg on May 03, 2024 12:04pm

latest news release

The newest release is interesting in that it is one of the first to NOT mention pre-BTD and only mentioned BTD approval.

Possibilities
a) vague wording and cannot read into it. (most likely)
b) pre-BTD has been done and they got the feedback to go ahead and submit BTD.

I would love it to be b.

One thing about pre-BTD is that I've never been convinced it is a thing in the way that people say. The BTD process allows meeting with FDA to run through the application and get feedback on whether it is good to go. I think that that part is what they have been labelling pre-BTD.

My thought/hope
- they ran it by pre-BTD staff to see if ready in 2023 and were told that it looks promising but that they weren't ready for BTD till got a,b,c
- they got enough a,b,c that they ran it by pre-reviewing staff again and they said that you are good to go but make sure you finalize these details.
- so perhaps what they have been calling pre-BTD is done and they have enough hope that they are hiring extra staff to run down details.

One thing about medical research in the setting where I work is that for them to get patient's to sign forms for the extended data follow up, they need to catch the patient. You can't cold call them. Not allowed. In my area the research person such as myself sees when the patient is coming and catches the doc before they go in and says, can you ask the patient if they will give permission to chat with me after the visit. They do the visit and come out and go to a sideroom for research signatures and explanations. You have to do all that because if you don't it just doesn't happen.

I wonder if they are having enough trouble catching the last few patients that the new hires are being tasked with literally going to the sites and being there for the patient visit to catch them like this. Docs are terrible at doing any research paperwork as they are just too rushed in clinic. The BTD is probably needing the full extended data set on the 20CRs.

These kind of thoughts are my copium. :)
Comment by managementfirst on May 03, 2024 12:29pm
Very thoughtful, but RDW just kept everything delaying, cannot rust him.
Comment by Infinity on May 06, 2024 11:29am
I  was just wondering what the newest Director on the TLT Borad is  doing in terms of creating awareness for this Novel treatment using the PDT.  Have not heard anything from DR.Kaouthar Lbiati since was invited to an independant director.  She was appointed almost a year ago on 3rd June, 2023.  Not a word from her, No mention in her Twitter "X" account as well ...more  
Comment by gebremeskel on May 06, 2024 1:43pm
You could always ask her - kaouthar.lbiati@gmail.com She may not be at liberty to share much information. I would guess she is quietly working behind the scenes. Theralase was happy enough with her performance 7 months ago to grant her 300,000 options at 25 cents.  She just had an interview in the online RootsandRoutesMag.Com which was founded by another member of the Moroccan diaspora ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250